{"title":"胰腺癌化疗诱发毒性的展望","authors":"H. Verma, Tarun Sahu, L. Bhaskar","doi":"10.25082/ccr.2023.01.005","DOIUrl":null,"url":null,"abstract":"Despite breakthroughs in screening, identification, and therapy, pancreatic cancer (PC) remains a serious issue in cancer-related mortality. This comprehensive review investigates the long-term and latent effects of chemotherapy in PC, focusing on commonly used medicines such as gemcitabine, docetaxel, irinotecan, nab-paclitaxel, and others. Gemcitabine, a common PC medication, causes a variety of adverse effects, including myelosuppression and weariness. Combination therapy, such as docetaxel and irinotecan, enhance toxicity, resulting in problems such as neutropenia and gastrointestinal difficulties. Significantly, chemotherapy-related complications, such as thrombosis and cardiac difficulties connected to paclitaxel, present serious concerns. Erlotinib, gefitinib, vatalanib, and sunitinib studies show significant side effects. Despite ongoing challenges, determining the causes of the low objective response rate in gemcitabine-refractory patients remains challenging. The study emphasizes the importance of future advances in cancer etiology, arguing for large, straightforward studies examining combination chemotherapies to improve tolerance and minimize chemotherapy-induced sequelae. This overview serves as a thorough guide for physicians, researchers, and policymakers as they navigate the complex terrain of PC chemotherapy, providing significant insights to improve patient care.","PeriodicalId":72728,"journal":{"name":"Current cancer reports","volume":"3 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Perspectives on chemotherapy-induced toxicities in pancreatic cancer\",\"authors\":\"H. Verma, Tarun Sahu, L. Bhaskar\",\"doi\":\"10.25082/ccr.2023.01.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Despite breakthroughs in screening, identification, and therapy, pancreatic cancer (PC) remains a serious issue in cancer-related mortality. This comprehensive review investigates the long-term and latent effects of chemotherapy in PC, focusing on commonly used medicines such as gemcitabine, docetaxel, irinotecan, nab-paclitaxel, and others. Gemcitabine, a common PC medication, causes a variety of adverse effects, including myelosuppression and weariness. Combination therapy, such as docetaxel and irinotecan, enhance toxicity, resulting in problems such as neutropenia and gastrointestinal difficulties. Significantly, chemotherapy-related complications, such as thrombosis and cardiac difficulties connected to paclitaxel, present serious concerns. Erlotinib, gefitinib, vatalanib, and sunitinib studies show significant side effects. Despite ongoing challenges, determining the causes of the low objective response rate in gemcitabine-refractory patients remains challenging. The study emphasizes the importance of future advances in cancer etiology, arguing for large, straightforward studies examining combination chemotherapies to improve tolerance and minimize chemotherapy-induced sequelae. This overview serves as a thorough guide for physicians, researchers, and policymakers as they navigate the complex terrain of PC chemotherapy, providing significant insights to improve patient care.\",\"PeriodicalId\":72728,\"journal\":{\"name\":\"Current cancer reports\",\"volume\":\"3 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current cancer reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25082/ccr.2023.01.005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25082/ccr.2023.01.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
尽管在筛查、识别和治疗方面取得了突破性进展,但胰腺癌(PC)仍然是癌症相关死亡率中的一个严重问题。本综述研究了化疗对 PC 的长期和潜在影响,重点关注吉西他滨、多西他赛、伊立替康、纳布紫杉醇等常用药物。吉西他滨是一种常见的 PC 药物,会引起多种不良反应,包括骨髓抑制和倦怠。多西他赛和伊立替康等联合疗法会增加毒性,导致中性粒细胞减少和胃肠道不适等问题。值得注意的是,与化疗相关的并发症,如紫杉醇引起的血栓形成和心脏问题,也令人严重担忧。厄洛替尼、吉非替尼、伐他拉尼和舒尼替尼的研究显示了明显的副作用。尽管挑战不断,但确定吉西他滨难治性患者客观反应率低的原因仍具有挑战性。该研究强调了未来在癌症病因学方面取得进展的重要性,主张开展大型、直接的研究,探讨联合化疗,以提高耐受性并尽量减少化疗引起的后遗症。这篇综述为医生、研究人员和政策制定者提供了全面的指导,帮助他们在PC化疗的复杂领域中游刃有余,为改善患者护理提供了重要的启示。
Perspectives on chemotherapy-induced toxicities in pancreatic cancer
Despite breakthroughs in screening, identification, and therapy, pancreatic cancer (PC) remains a serious issue in cancer-related mortality. This comprehensive review investigates the long-term and latent effects of chemotherapy in PC, focusing on commonly used medicines such as gemcitabine, docetaxel, irinotecan, nab-paclitaxel, and others. Gemcitabine, a common PC medication, causes a variety of adverse effects, including myelosuppression and weariness. Combination therapy, such as docetaxel and irinotecan, enhance toxicity, resulting in problems such as neutropenia and gastrointestinal difficulties. Significantly, chemotherapy-related complications, such as thrombosis and cardiac difficulties connected to paclitaxel, present serious concerns. Erlotinib, gefitinib, vatalanib, and sunitinib studies show significant side effects. Despite ongoing challenges, determining the causes of the low objective response rate in gemcitabine-refractory patients remains challenging. The study emphasizes the importance of future advances in cancer etiology, arguing for large, straightforward studies examining combination chemotherapies to improve tolerance and minimize chemotherapy-induced sequelae. This overview serves as a thorough guide for physicians, researchers, and policymakers as they navigate the complex terrain of PC chemotherapy, providing significant insights to improve patient care.